-+ 0.00%
-+ 0.00%
-+ 0.00%

Chosa Oncology enters non-exclusive licensing pact with Aida Oncology

PUBT·08/27/2026 12:40:32
Listen to the news
Chosa Oncology enters non-exclusive licensing pact with Aida Oncology
  • Chosa Oncology entered a non-exclusive licensing agreement with Aida Oncology to expand precision oncology offerings for commercialization.
  • Deal grants Aida rights to use Platin-DRP within breast cancer.
  • Chosa receives rights to use Aida’s TaxaTect taxane drug-response predictor within lung cancer.
  • Partnership follows a joint prediction study presented at the ASCO Annual Meeting 2026 supporting combined use in early breast cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief via Cision (Ref. ID: 20260827:BIT:3105:0) on August 27, 2026, and is solely responsible for the information contained therein.